Gut related inflammation and cardiorespiratory fitness in patients with CAD and type 2 diabetes: a sub-study of a randomized controlled trial on exercise training

Susanne Kristine Aune1,2*, Rune Byrkjeland1, Svein Solheim1,3, Harald Arnesen1,2, Marius Trøseid2,4, Ayodeji Awoyemi1,2, Ingebjørg Seljeflot1,2,3 and Ragnhild Helseth1,3

Abstract

Aim: Gut leakage has been shown to associate with low-grade inflammation and lower cardiorespiratory fitness in diabetic subjects. We aimed to investigate whether gut leakage markers related to cardiorespiratory fitness in patients with both coronary artery disease and type 2 diabetes, and whether these were affected by long-term exercise training.

Methods: Patients with angiographically verified coronary artery disease and type 2 diabetes mellitus (n = 137) were randomized to either 12 months exercise intervention or conventional follow-up. A cardiopulmonary exercise test and fasting blood samples were obtained before and after intervention to assess VO2peak and the biomarkers soluble CD14, lipopolysaccharide-binding protein and intestinal fatty-acid binding protein as markers of gut leakage.

Results: 114 patients completed the intervention satisfactory. VO2peak correlated inversely to sCD14 (r = −0.248, p = 0.004) at baseline. Dividing sCD14 into quartiles (Q1), VO2peak was significantly higher in Q1 vs. Q2–4 (p = 0.001), and patients in Q2-4 (sCD14 > 1300 ng/mL) had an OR of 2.9 (95% CI 1.2–7.0) of having VO2peak below median (< 23.8 ml/kg/min) at baseline. There were no statistically significant differences in changes in gut leakage markers between the two randomized groups (all p > 0.05) after 12 months.

Conclusions: Cardiorespiratory fitness related inversely to sCD14, suggesting physical capacity to be associated with gut leakage in patients with CAD and T2DM. Long-term exercise training did not affect circulating gut leakage markers in our population.

Trial registration NCT01232608, Registered 02 November 2010—Retrospectively registered at https://clinicaltrials.gov/ct2/show/NCT01232608?term=NCT01232608&draw=2&rank=1

Keywords: Coronary artery disease, Type 2 diabetes, Cardiovascular fitness, Gut leakage, Inflammation, Exercise intervention

Introduction

Intestinal dysbiosis and gut leakage is hypothesized to contribute to the chronic low-grade inflammatory state associated with obesity, insulin resistance and...
atherosclerotic cardiovascular disease (CVD) [1, 2]. Gut leakage describes the translocation of bacterial wall products, mainly lipopolysaccharide (LPS), across the gut barrier by either para- or transcellular mechanisms, or by enterocyte damage with subsequent leakage of the intracellular intestinal fatty acid-binding protein (I-FABP) into the circulation [3]. LPS in the circulation interacts with LPS-binding protein (LBP), membrane bound or soluble CD14 (sCD14), activating the toll-like receptor 4 (TLR4) and initiating downstream inflammatory signaling [4]. Elevated levels of LBP and sCD14 have been associated not only with insulin resistance and obesity [5], but also with coronary artery disease (CAD) and all-cause mortality [6, 7]. As levels of LBP and sCD14 have been shown to correlate with LPS, they are acknowledged surrogate markers for endotoxemia [8]. However, an increase in sCD14 is not restricted to LPS exposure, but can be regarded as a marker of monocyte activation [9]. I-FABP is regarded as a marker of intestinal injury or ischemia [10].

Regular physical exercise is recommended by the European Society of Cardiology for prevention of cardiovascular events and all-cause mortality, and is associated with a beneficial cardio-metabolic profile and decrease in markers of systemic inflammation [11]. Furthermore, a combination of aerobic and resistance training has been shown to improve insulin sensitivity and glycemic control in subjects with T2DM [12]. Exercise has also been hypothesized to contribute to increased gut microbial diversity, and thus a less leaky gut [13]. In healthy subjects, microbial diversity has been shown to associate with cardiorespiratory fitness [14], whereas in diabetic and pre-diabetic subjects gut leakage markers have been reported elevated, and importantly, modifiable by exercise [15]. However, the link between physical fitness and effects of exercise training on markers of gut leakage has not been extensively studied, particularly in patients with CAD. Our aims were therefore to explore the relationship between cardiorespiratory fitness and gut leakage markers in patients with combined CAD and T2DM. We hypothesized that less aerobically fit patients have higher levels of gut leakage markers than fit patients. Secondly, we aimed to investigate whether long-term exercise can impact circulating gut leakage markers in patients with T2DM and CAD. Our hypothesis was that exercise would reduce gut leakage.

Methods
Study population
The present investigation is a sub-study of the “Exercise training in patients with coronary artery disease and type 2 diabetes” (EXCADI) study [16]. Patients with combined T2DM and angiographically verified CAD (n = 137) were included at Department of Cardiology, Oslo University Hospital, Oslo, Norway, between August 2010 and March 2012. The study design has previously been described in detail, and the methods description partly reproduces their wording [16]. In brief, patients were randomized 1:1 to a combination of strength and endurance training with an instructor or to a control group with conventional follow-up by their general practitioner. Patients in the control group were not discouraged to exercise. Diabetic microvascular complications were defined as a history of nephropathy, neuro- or retinopathy, and/or abnormal monofilament test and/or (micro-) albuminuria. Patients with previous myocardial infarction (MI) and/or diabetic complications were defined to have advanced vascular disease. Hypertension (HT) was defined as use of antihypertensive medication.

Exclusion criteria were presence of proliferative retinopathy, end-stage renal disease, cancer, stroke or acute MI within the last 3 months, unstable angina, decompensated heart failure, serious arrhythmia, severe valvular disease, severe rheumatologic disease, chronic obstructive pulmonary disease stadium GOLD IV, thromboembolic disease, ongoing infections, severe musculoskeletal disorders, or other disabilities limiting the ability for physical activity.

Cardiopulmonary exercise test
A cardiopulmonary exercise test using a modified Balke protocol was performed on treadmill before the intervention and approximately one week after the last exercise session [17]. The procedure has previously been described [18]. It was continued until exhaustion or until ended by the physician for safety reasons. Gas exchange was continuously measured by breathing into a Hans Rudolph two-way breathing mask (2700 series; Hans Rudolph Inc, Kansas City, USA), connected to a metabolic cart (Vmax SensorMedics, Yorba Linda, USA) assessing ventilation, oxygen and carbon dioxide content of expired air. VO2peak was defined as the highest average oxygen uptake of consecutive 30 s during the test. The achieved VO2peak was also included if the test had to be terminated because of functional limitations. Maximal respiratory exchange ratio (RER) was measured. The anaerobic threshold (AT) was estimated by the ventilatory equivalent method [19].

Physical exercise intervention
The exercise group underwent a 12-month training intervention. The physical exercise program was developed and conducted in collaboration with the Norwegian School of Sport Sciences (NIH). Details on the exercise program have previously been described [16]. In brief, the exercise group participated in a total of 150 min of
training per week, divided into supervised group-based training sessions of combined aerobic and resistance training two times a week, with an additional home-based individual exercise once a week. The Borg’s rated perceived exertion (RPE) scale was used to guide exercise intensity [20].

**Laboratory methods**
Venous blood samples were drawn in fasting conditions by standard venipuncture between 08:00 and 10:00 a.m. before intake of morning medication at time of inclusion and after 1 year. Routine blood samples including HbA1c, insulin, CRP and C-peptide were determined by conventional laboratory methods. Insulin resistance was estimated by the updated homeostatic model assessment indexes for insulin resistance (HOMA2-IR). Glucose and insulin values were entered in the computer model to calculate HOMA2-IR [21].

A biobank was established. Serum was prepared by centrifugation within 1 h at 2500g for 10 min, and EDTA plasma was prepared by centrifugation within 1 h at 2700g for 20 min at 4 °C, both kept frozen at − 80 °C until analyses. I-FABP was determined in serum, measured by enzyme-linked immunosorbent assay (ELISA) (Hycult Biotech, Uden, the Netherlands). sCD14 and LBP were measured in EDTA plasma by ELISAs (R&D Systems Europe, Abingdon, Oxon, UK and Hycult Biotech, respectively). The inter-assay coefficients of variation (CV) were 17.3%, 10.9% and 8.1% respectively.

**Statistical analysis**
Demographic data are given as proportions, mean (± SD) or median (25th and 75th percentiles) depending on the data distribution. Differences between groups at baseline were analyzed by Chi square test for categorical data and Mann–Whitney U test or Kruskal–Wallis Test as appropriate for continuous data. Correlation analyses were performed by Spearman’s Rho. A univariate logistic regression model was used to estimate odds ratio for peak VO2 according to levels of sCD14, and a multivariate regression analysis was used to adjust for variables known to influence peak VO2 (age, sex and BMI). Receiver operating characteristic (ROC) curve was performed to explore any predictive value of I-FABP1 for the presence of microvascular complications. Changes in biomarkers from baseline to end of intervention are given as absolute and relative changes. Within-group changes were analyzed by Wilcoxon Signed Rank test, and differences in changes and relative changes between groups were analyzed by Mann–Whitney U test. Statistical calculations were performed using SPSS version 25 (SPSS, Inc., Chicago, IL, USA). p-values < 0.05 were considered statistically significant.

**Results**

**Patient characteristics at baseline**
Baseline characteristics are presented in Table 1. Of the 137 included patients, 123 completed the study. Patients with the lowest adherence to the training intervention (< 40% adherence) were excluded (n = 9) from the per protocol analyses [16]. Thus, 114 patients were analyzed for the intervention effect; 52 in the exercise group and 62 in the control group. There were no significant differences between the intervention groups at baseline.

There were no significant differences between the groups in changes in weight, waist circumference, energy intake, percentage intake of main nutrients or diabetes medication during the study period, as previously reported [16]. There was also no significant difference in basal metabolic rate (BMR) between the groups at baseline or significant difference in change between the groups after the intervention (data not shown).

**Gut-related biomarkers and cardiorespiratory fitness at baseline**

As outlined in Table 2, the intervention groups were comparable as to physical performance at baseline. During the cardiorespiratory exercise test, one hundred and twenty-seven patients (93%) reached RER > 1.10 and/or Borg scale (6–20) > 17. Levels of the gut leakage markers at baseline are also presented in Table 2. The gut leakage markers did not differ between the two randomized groups at baseline.

In the total population, VO2peak was inversely correlated to sCD14 (p = 0.004) (Table 3, Additional file 2: Figure S1) and CRP (r = − 0.320, p < 0.001). Otherwise, no significant correlations between markers of gut-related inflammation and variables reflecting physical performance were observed.

VO2peak levels differed significantly between quartiles of sCD14 (p = 0.005) (Fig. 1). Based on a visual cut-off between the lowest quartile (Q1) and the three highest quartiles (Q2–4) (Fig. 1, arrow), sCD14 was dichotomized into Q1 and Q2–4 for further analyses. VO2peak was significantly lower in Q2–4 compared to Q1 (p = 0.001) (Fig. 2). Patients in Q2–4 (sCD14 > 1300 ng/mL) had an odds ratio (OR) of 3.2 (95% CI 1.4–7.5) of having a VO2peak below median (< 23.8 mL/kg/min). The results were still significant after adjusting for age, sex and BMI, with an OR of 2.9 (95% CI 1.2–7.0).

**Markers of gut leakage, glucometabolic state and diabetic complications**
Levels of sCD14 at baseline correlated significantly to fasting blood glucose (r = 0.174, p = 0.044), but not to HbA1c, HOMA2-IR and diabetes duration (Additional file 1: Table S1). LBP correlated significantly to waist...
Aune et al. Diabetol Metab Syndr (2021) 13:36

Effect of exercise on markers of gut leakage

Changes in markers of gut leakage according to the intervention groups from baseline to 12 months are illustrated in Fig. 3. Relative changes during the intervention are presented in Fig. 4. As previously reported, there was a non-significant increase in mean VO2peak in the exercise group of 0.8 mL/kg/min (95% CI −0.2 to 1.8; \( p = 0.107 \)), and the difference in change from baseline to 12 months was not significant between the exercise group and the control group [16]. The exercise intervention did not significantly affect the gut leakage markers after 12 months, neither in absolute nor in relative numbers (Figs. 3 and 4). The same lack of intervention effect was observed for patients without advanced vascular disease (\( n = 46 \)). For patients in the intervention group who increased their VO2peak numerically during the intervention period (\( n = 28 \)), no significant changes in gut leakage markers were observed (data not shown).

There were no significant within group changes from baseline to 12 months in any of the gut leakage markers, but not to any glucometabolic variable. Patients with microvascular complications had significantly higher I-FABP than patients without these diabetic complications (\( p = 0.010 \)), with an AUC of 0.66 (95% CI 0.56, 0.77) in ROC curve analysis (\( p = 0.010 \)).

**Table 1** Baseline characteristics of the total population and according to randomized groups

|                        | All (\( n = 137 \)) | Exercise (\( n = 52 \)) | Control (\( n = 62 \)) |
|------------------------|---------------------|--------------------------|------------------------|
| Age (years)\(^a\)      | 64 [41, 81]         | 65 [48, 81]              | 65 [41, 77]            |
| Sex (male), \( n, \% \) | 115 (83.9)          | 45 (86.5)                | 50 (80.6)              |
| BMI\(^b\) (kg/m\(^2\)) | 28.7 (25.6, 31.6)   | 29.4 (25.6, 31.8)        | 28.3 (25.4, 31.5)      |
| Duration of diabetes (years) | 9 (5, 15)         | 11 (5, 15)               | 9 (5, 13)              |
| Previous MI, \( n, \% \) | 62 (45.3)           | 20 (38.5)                | 31 (50.0)              |
| Microvascular complications\(^d\) | 26 (19)           | 7 (13.5)                 | 10 (16.1)              |
| Advanced vascular disease, \( n, \% \) | 85 (62.0)         | 28 (53.8)                | 40 (64.4)              |
| Hypertension, \( n, \% \) | 100 (73.0)          | 39 (75.0)                | 46 (74.2)              |
| Current smokers, \( n, \% \) | 23 (16.8)          | 9 (17.3)                 | 9 (14.5)               |
| HbA1c\(^e\) (%)       | 7.4 (6.8, 8.3)      | 7.4 (6.8, 8.4)           | 7.3 (6.8, 7.9)         |
| Fasting blood glucose | 8.1 (6.9, 9.8)      | 7.5 (6.7, 9.9)           | 8.0 (6.8, 9.6)         |
| HOMA2-IR\(^f\)        | 1.3 (0.7, 2.1)      | 1.1 (0.7, 1.9)           | 1.3 (0.7, 2.2)         |
| Total cholesterol (mmol/L) | 3.9 (3.4, 4.5)   | 3.8 (3.4, 4.3)           | 4 (3.3, 4.7)           |
| Triglycerides (mmol/L)  | 1.4 (1.0, 1.9)      | 1.4 (1.1, 1.9)           | 1.4 (1.0, 1.9)         |
| LDL\(^g\) cholesterol (mmol/L) | 2.0 (1.6, 2.6)  | 1.8 (1.5, 2.5)           | 2.1 (1.6, 2.7)         |
| CRP\(^h\) (mg/L)      | 2.6 (1.2, 5.0)      | 2.0 (0.9, 4.9)           | 2.4 (1.2, 5.0)         |
| Medication             |                     |                          |                        |
| RAAS inhibitors, \( n, \% \) | 97 (70.8)         | 34 (65.4)                | 46 (74.2)              |
| Statins, \( n, \% \)  | 128 (93.4)          | 49 (94.2)                | 58 (93.5)              |
| Metformin, \( n, \% \) | 101 (73.7)          | 40 (76.9)                | 46 (74.2)              |
| Sulfonylureas, \( n, \% \) | 48 (35.0)         | 23 (44.2)                | 17 (27.4)              |
| Glipitin, \( n, \% \)  | 17 (12.4)           | 6 (11.5)                 | 11 (17.7)              |
| Insulin, \( n, \% \)   | 26 (19.0)           | 10 (19.2)                | 12 (19.4)              |
| Antiplatelet medication, \( n, \% \) | 129 (94.2)      | 47 (90.4)                | 61 (98.4)              |

Data are presented as median (25, 75 percentiles) if not stated otherwise

\(^a\) Median [min, max]

\(^b\) Body mass index

\(^c\) Myocardial infarction

\(^d\) Microvascular complications were defined as a history of nephron-, neuro- or retinopathy, and/or abnormal monofilament test and/or (micro-) albuminuria

\(^e\) Advanced vascular disease was defined as patients having previous myocardial infarction and/or diabetic microvascular complications in addition to coronary artery disease

\(^f\) Glucose and insulin values were entered in the computer model to calculate HOMA2-IR

\(^g\) Low-density lipoprotein

\(^h\) C-reactive protein

circumference (\( r = 0.198, p = 0.023 \)), but not to any glucometabolic variable. Patients with microvascular complications had significantly higher I-FABP than patients without these diabetic complications (\( p = 0.010 \)), with an AUC of 0.66 (95% CI 0.56, 0.77) in ROC curve analysis (\( p = 0.010 \)).
markers, neither in the exercise nor the control group (data not shown).

**Discussion**

This study aimed to explore the relationship between cardiorespiratory fitness and markers of gut leakage in patients with combined T2DM and CAD. Our main finding was a significant inverse association between VO$_2$peak and levels of sCD14 and CRP, indicating increased monocyte activation and inflammation, and possibly increased gut leakage, in individuals with poorer cardiorespiratory fitness. We did not, however, find any significant association with LBP, which is a more robust marker of gut leakage markers, neither in the exercise nor the control group (data not shown).

**Table 2** Physical performance and levels of gut leakage markers in all patients, and according to intervention groups at baseline

|                          | All (n = 137) | Exercise (n = 52) | Control (n = 62) | p-values |
|--------------------------|--------------|------------------|------------------|----------|
| Exercise time (min:sec)  | 8.23 ± 0.239 | 8.05 ± 0.223     | 8.47 ± 2.46      | 0.153    |
| Maximal RER$^a$          | 1.17 (1.08, 1.23) | 1.16 (1.04, 1.23) | 1.16 (1.09, 1.23) | 0.260    |
| Maximal Borg rating scale (6–20)$^a$ | 17 (17, 19) | 17 (17, 18)     | 18 (17, 19)      | 0.106    |
| VO$_{2\text{peak}}$ (mL/kg/min) | 24.7 ± 5.9 | 24.4 ± 5.3       | 25.0 ± 6.6       | 0.556    |
| VO$_{2\text{peak}}$ (L/min) | 2.17 ± 0.56 | 2.16 ± 0.52      | 2.18 ± 0.59      | 0.868    |
| AT (mL/kg/min)           | 18.9 ± 4.1  | 18.9 ± 3.9       | 19.9 ± 4.6       | 0.263    |
| AT (L/min)               | 1.68 ± 0.42 | 1.69 ± 0.36      | 1.75 ± 0.47      | 0.466    |
| sCD14 (ng/mL)$^a$        | 1504 (1299, 1760) | 1550 (1334, 1710) | 1435 (1276, 1792) | 0.456    |
| LBP (µg/mL)$^a$          | 13.1 (10.3, 17.1) | 12.7 (9.2, 15.8) | 12.7 (10.6, 16.4) | 0.562    |
| I-FABP (pg/mL)$^a$       | 988 (783, 1497) | 1004 (766, 1561) | 971 (844, 1529)  | 0.891    |

Data are presented as mean ± SD if not stated otherwise. p-values are given for differences between the randomized groups. p-values < 0.05 were considered statistically significant. 

RER Respiratory exchange rate, AT anaerobic threshold, VO$_{2\text{peak}}$ Peak oxygen uptake 

$^a$ Median (25, 75 percentiles)

**Table 3** Coefficients of correlation between gut leakage markers and physical fitness at baseline

|                      | VO$_{2\text{peak}}$ (ml/kg/min) | AT (ml/kg/min) |
|----------------------|----------------------------------|----------------|
| sCD14                | $r = -0.248$                       | $r = -0.132$   |
|                      | $p = 0.004$                        | $p = 0.172$    |
| LBP                  | $r = -0.070$                       | $r = -0.103$   |
|                      | $p = 0.419$                        | $p = 0.289$    |
| I-FABP               | $r = -0.059$                       | $r = -0.001$   |
|                      | $p = 0.498$                        | $p = 0.993$    |

AT anaerobic threshold, VO$_{2\text{peak}}$ Peak oxygen uptake. p-values < 0.05 were considered statistically significant
leakage. There was no significant effect of 12 months exercise intervention on levels of gut leakage markers. This is, to the best of our knowledge, the first report on the relationship between cardiorespiratory fitness and gut leakage markers in patients with combined T2DM and CAD.

Although we did not measure the gut microbial composition or LPS levels per se, LPS is a potent stimulator of sCD14 release [22]. Our result showing low cardiorespiratory fitness to be associated with high levels of sCD14 could indicate a relationship to a dysbiotic and leaky gut. sCD14 has, however, been shown to be released upon interaction with other TLR ligands and inflammatory cytokines as well [9], and could therefore be considered a marker of monocyte activation and inflammation in general, not necessarily restricted to LPS and TLR4 interaction. The observed similar inverse relationship between CRP and VO2peak in our patients supports the theory of a general inflammatory process.

The underlying mechanisms by which a dysbiotic intestinal microbiota, gut leakage and cardiorespiratory fitness interact remain vastly unexplained. Our cross-sectional study of the baseline association limits our possibility of suggesting any causality, but previous studies link both intestinal dysbiosis and low cardiorespiratory fitness to a state of low-grade inflammation [2, 23]. Chronic inflammation is also present in obesity [24], but our findings were significant even after adjusting for BMI. Collectively, these results allow us to speculate that change in gut permeability and subsequent gut leakage is linked to the activation of inflammatory signaling pathways, being relevant in T2DM, atherosclerosis and cardiorespiratory fitness. However, one cannot rule out the possibility that patients with higher inflammation have greater cytokine-induced fatigue and are less likely to exercise, and therefore have lower baseline VO2peak and higher sCD14.

Beyond significant higher levels of I-FABP in patients with microvascular complications, the investigated gut leakage markers did not correlate to glucose control or any marker of glucometabolic state, except for a significant association between sCD14 and fasting blood glucose ($p=0.044$). The significant correlation found...
between LBP and waist circumference, is in line with previous studies reporting LBP to be elevated in obesity and in patients with an unhealthy adipose tissue distribution [25].

**Effect of exercise training**

There were no significant changes in any of the gut leakage markers after 12 months of combined resistance and endurance training. We have previously reported that the exercise group overall did not improve their VO$_{2\text{peak}}$, whereas patients without advanced vascular disease did [16]. As we found sCD14 linked to cardiorespiratory fitness, we hypothesized that levels of sCD14 would be reduced in those who increased their VO$_{2\text{peak}}$ during the exercise period, but no such relationship was found. It is possible that this group of patients, with both CAD and several years of diabetes with various macro- and microvascular complications, had too advanced disease to reach the presumed effect on reduction in gut leakage markers after 12 months. We could, however, not find any effect of exercise on the gut leakage markers when analyzing patients without advanced vascular disease separately.

The lack of intervention effect in the current study could also be due to lack of power, as power calculations were not specifically performed for the present hypothesis. It may also have been affected by the extent of exercise adherence, which was quite low, with an average of 67% (55%, 83%) [16]. However, it is unclear how much exercise is needed for patients to benefit from it, although we do know that 150/min per week is recommended on a general basis for patients with T2DM [26], and supervised combined resistance and endurance training has been shown to be the best [27].

Our patients were all on medication, of which several are known to have immunomodulatory effects to some extent. Almost 74% of the patients were on metformin that has been shown to have a variety of immunomodulatory effects [28]. Although the mechanisms of action and clinical relevance are unclear, and we found no significant difference between patients on and without metformin (data not shown), it is possible that any exercise effect on levels of gut leakage and inflammation, could be masked by metformin usage. In addition, over 90% were on aspirin, known to have anti-inflammatory effects [29], and 35% were on sulfonylureas, which also seem to possess anti-inflammatory properties [30]. This might have modulated the inflammatory response to LPS exposure in our patients, and could have attenuated the measurable effect of the exercise intervention.

**Limitations**

The main limitation of our study is that it was initially designed for the purpose of studying the effect of exercise training on HbA1c [16], thus not for considering effects on the investigated gut leakage markers. Although patients with ongoing infections were excluded from the study at baseline, there was no exclusion of patients who had used antibiotic treatment in the months prior to inclusion. Other studies have excluded patients using antibiotics up to 6 months prior to inclusion [14]. We have not measured levels of LPS, which may have added to the results. However, LPS is unstable in the circulation, and the most used laboratory method for LPS quantification, the limulus amebocytes lysate assay, is encumbered with limitations. We also did not analyze the interventional effects on the microbiota itself. Finally, although we know that different diets alter the gut microbiota differently, we did not control the participants’ diet in details during the intervention [31].

**Conclusion**

The inverse association demonstrated between VO$_{2\text{peak}}$ and levels of sCD14 and CRP, suggests a significant interaction between cardiorespiratory fitness and gut-related inflammation in our patients with both type 2 diabetes and coronary artery disease.

A 12 months exercise intervention program did, however, not affect gut leakage markers in this patient group.

**Abbreviations**

CAD: Coronary artery disease; CVD: Cardiovascular disease; T2DM: Type 2 diabetes mellitus; VO$_{2\text{peak}}$: Peak oxygen uptake; sCD14: Soluble cluster of differentiation 14; LPS: Lipopolysaccharide; LBP: LPS-binding protein; I-FABP: Intestinal fatty-acid binding protein; TLR4: Toll-like receptor 4; GOLD: Global initiative for chronic obstructive lung disease; MI: Myocardial infarction; AT: Anaerobic threshold; RER: Respiratory exchange ratio; RPE: Rated perceived exertion; ELISA: Enzyme-linked immune sorbent assay; HOMA2-IR: Updated homeostatic model assessment of insulin resistance; SCFA: Short chain fatty acid; EXCADI: Exercise training in patients with coronary heart disease and Type 2 diabetes.

**Supplementary Information**

The online version contains supplementary material available at https://doi.org/10.1186/s13098-021-00655-2.

**Additional file 1**

Table S1. Baseline correlations between markers of gut leakage and glucometabolic state are presented in this table.

**Additional file 2**

Figure S1. Correlation plot between VO$_{2\text{peak}}$ and sCD14 at baseline.

**Acknowledgements**

The authors want to thank Ida Unhammer Njerve, Vibeke Bratseth, Sissel Åkra, Jeanette Konstanse Steen and Elisabeth Edvardsen for valuable contributions to the study.
Authors’ contributions
SKA contributed to planning of the study, did most of the laboratory work, statistical analyses, interpretation of results and prepared the initial draft of the manuscript. RB was a major contributor in the conduct of the EXCADI study and to the intellectual content and discussion of the manuscript. SS and HA contributed in the planning of the study and to the intellectual content and discussion of the manuscript. MT contributed to the planning of the laboratory analyses, to the interpretation of the results and to the intellectual content and discussion of the manuscript. AA contributed to the intellectual content and discussion of the manuscript. IS and RH were major contributors in the planning and conduct of the study, statistical analysis, interpretation of the results and the intellectual content. All authors read and approved the final manuscript.

Funding
This work was supported by the Stein Erik Hagen Foundation for Clinical Heart Research, and the Ada og Hagbart Waages Humanitære og Veldedige Stiftelse, Oslo, Norway. The funding source had no involvement in any part of the study, or in the scientific writing, nor in the decision to submit the manuscript for publication.

Availability of data and materials
The datasets used and analyzed during the current study are available from the corresponding author on reasonable request.

Competing interests
The authors declare that they have no competing interest.

Declarations

Ethics approval and consent to participate
The study was approved by the Regional Committee of Medical Research Ethics in South-Eastern Norway and conducted in accordance with the Declaration of Helsinki, and is registered at http://www.clinicaltrials.gov NCT01232608. All patients gave their written informed consent to participate.

Consent for publication
Not applicable.

Competing interests
The authors declare that they have no competing interest.

Author details
1 Center for Clinical Heart Research, Department of Cardiology, Oslo University Hospital Ullevål, Ullevål Pb 4956 Nydalen, 0424 Oslo, Norway. 2 Faculty of Medicine, University of Oslo, Oslo, Norway. 3 Department of Cardiology, Oslo University Hospital Ullevål, Oslo, Norway. 4 Section of Clinical Immunology and Infectious Diseases, Oslo University Hospital Rikshospitalet, Oslo, Norway.

Received: 13 January 2021 Accepted: 20 March 2021
Published online: 01 April 2021

References
1. Ascher S, Reinhardt C. The gut microbiota: an emerging risk factor for cardiovascular and cerebrovascular disease. Eur J Immunol. 2018;48(4):564–75.
2. Saad MJ, Santos A, Prada PO. Linking gut microbiota and inflammation to obesity and insulin resistance. Physiology. 2016;31(4):283–93.
3. Ghosh SS, Wang J, Yannse PJ, Ghosh S. Intestinal barrier dysfunction, LPS translocation, and disease development. J Endocr Soc. 2020. https://doi.org/10.1210/jendso/bvz039.
4. Płocinikowska A, Hromada-Judycka A, Borzecka K, Kwiatkowska KJC, Sciences ML. Co-operation of TLR4 and raft proteins in LPS-induced pro-inflammatory signaling. Cell Mol Life Sci. 2015;72(3):557–81.
5. Moreno-Navarrete JM, Ortega F, Serino M, Luche E, Waget A, Pardo G, et al. Circulating lipopolysaccharide-binding protein (LBP) as a marker of obesity-related insulin resistance. Int J Obes. 2012;36(1):1442–9.
6. Reiner AP, Lange EM, Jenny NS, Chaves PH, Ellis J, Li J, et al. Soluble CD14: genomewide association analysis and relationship to cardiovascular risk and mortality in older adults. Arterioscler Thromb Vasc Biol. 2013;33(1):158–64.
7. Lepper PM, Schumann C, Triantafillou K, Rasche FM, Schuster T, Frank H, et al. Association of lipopolysaccharide-binding protein and coronary artery disease in men. J Am Coll Cardiol. 2007;50(1):25–31.
8. Batton LS, Lee OM, Weir TL, Gentile CL. The gut microbiota as a novel regulator of cardiovascular function and disease. J Nutr Biochem. 2018;56:1–15.
9. Shive CL, Jiang W, Anthony DD, Lederman MM. Soluble CD14 is a nonspecific marker of monocyte activation. AIDS. 2015;29(10):1263–5.
10. Timmermans K, Sir O, Kox M, Vaneker M, de Jong C, Gerretsen J, et al. Circulating IFNβ levels as a marker of intestinal damage in trauma patients. Shock. 2015;43(2):117–20.
11. Piepoil MF, Hoes AW, Agewali S, Albus C, Brotons C, Catapano AL, et al. 2016 European Guidelines on cardiovascular disease prevention in clinical practice: the sixth joint task force of the European Society of Cardiology and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of 10 societies and by invited experts) developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR). Eur Heart J. 2016;37(29):2315–81.
12. Codello R, Lalacqua M, Terruzzi L, Luzi L. May the force be with you: why resistance training is essential for subjects with type 2 diabetes mellitus without complications. Endocrine. 2018;62(1):14–25.
13. Monda V, Villano I, Messina A, Valenzano A, Esposito T, Moscatelli F, et al. Exercise modifies the gut microbiota with positive health effects. Oxid Med Cell Longev. 2017;2017:3831972.
14. Estaki M, Pither J, Baumeister P, Little JP, Gill SK, Ghosh S, et al. Cardiorespiratory fitness as a predictor of intestinal microbial diversity and distinct metagenomic functionalities. Microbiome. 2016;4(1):42.
15. Mozani KH, Collado MC, Eskelinen JJ, Virtanen KA, LÖyttyniemi E, Salmi-Suksi S, et al. Exercise training modulates gut microbiota profile and improves endotoxemia. Med Sci Sports Exerc. 2020;52(1):94–104.
16. Byrkjeland R, Njerve IU, Anderssen S, Arnøsen H, Seljeiloft I, Solheim S. Effects of exercise training on HbA1c and VO2peak in patients with type 2 diabetes and coronary artery disease: a randomised clinical trial. Diab Vasc Dis Res. 2015;12(5):325–33.
17. Balke B, Ware RW. An experimental study of physical fitness of Air Force personnel. UN Armed Forces Med J. 1959;10(6):675–88.
18. Byrkjeland R, Edvardsen E, Njerve IU, Arnøsen H, Seljeiloft I, Solheim S. Insulin levels and HOMA index are associated with exercise capacity in patients with type 2 diabetes and coronary artery disease. Diabetol Metab Syndr. 2014;6(1):36.
19. Wasserman K. Principles of exercise testing and interpretation: including pathophysiology and clinical applications. 5th ed. Philadelphia: Wolters Kluwer Health/Lippincott Williams & Wilkins. 2012.
20. Borg GA. Perceived exertion. Exerc Sport Sci Rev. 1974;2:131–53.
21. Wallace TM, Levy JC, Matthews DR. Use and abuse of HOMA modeling. Diabetes Care. 2004;27(6):1487–95.
22. Pugin J, Schurer-Maly CC, Leturcq D, Moriarty A, Ulevitch RJ, Tobias PS. Lipopolysaccharide activation of human endothelial and epithelial cells is mediated by lipopolysaccharide-binding protein and soluble CD14. Proc Natl Acad Sci USA. 1993;90(7):2744–8.
23. Wedell-Neergaard A-S, Krogh-Madsen R, Petersen GI, Hansen ÅM, Pedersen BK, Lund R, et al. Cardiorespiratory fitness and the metabolic syndrome: roles of inflammation and abdominal obesity. PLoS ONE. 2018;13(3):e0194991.
24. Esser N, Legrand-Poels S, Piette J, Scheen AJ, Paquot N. Inflammation as a link between obesity, metabolic syndrome and type 2 diabetes. Diabetes Res Clin Pract. 2014;105(2):141–50.
25. Awoyemi A, Troseid M, Arnøsen H, Solheim S, Seljeiloft I. Markers of metabolic endotoxemia as related to metabolic syndrome in an elderly male population at high cardiovascular risk: a cross-sectional study. Diabetol Metab Syndr. 2018;10:59.
26. Marwick TH, Hordern MD, Miller T, Chyyn DA, Bertoni AG, Blumenthal RS, et al. Exercise training for type 2 diabetes mellitus: impact on cardiovascular risk: a scientific statement from the American Heart Association. Circulation. 2009;119(25):3242–62.
27. Pan B, Ge L, Xun YQ, Chen YJ, Gao CY, Han X, et al. Exercise training modalities in patients with type 2 diabetes mellitus: a systematic review and meta-analysis. Int J Behav Nutr Phys Act. 2018;15(1):72.
28. Minamii T, Nogami M, Ogawa W. Mechanisms of metformin action: in and out of the gut. J Diabetes Invest. 2018;9(4):701–3.
29. Montinari MR, Minelli S, De Caterina R. The first 3500 years of aspirin history from its roots—a concise summary. Vascul Pharmacol. 2019;113:1–8.
30. Yaribeygi H, Atkin SL, Piro M, Sahebkar A. A review of the anti-inflammatory properties of antidiabetic agents providing protective effects against vascular complications in diabetes. J Cell Physiol. 2019;234(6):8286–94.

31. Moreira APB, Texeira TFS, Ferreira AB, Peluzio MdCG, Alfenas RdCG. Influence of a high-fat diet on gut microbiota, intestinal permeability and metabolic endotoxaemia. Br J Nutr. 2012;108(5):801–9.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.